Half-Life Cancer Research Results
Half-Life, Half-Life: Click to Expand ⟱
| Source: |
| Type: |
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.
|
NA, Not Available: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
Half-Life↝, Dose↝, Dose↝,
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
Half-Life↝, BioAv↓, Half-Life↝, BioAv↓,
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
| - |
vitro+vivo, |
PC, |
MIA PaCa-2 |
|
|
|
- |
in-vitro, |
NA, |
PANC1 |
|
|
|
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
ChemoSideEff↓, ROS↑, H2O2↑, Fenton↑, Hif1a↝, Dose↑, BioAv↓, Dose↝, Half-Life↝, IL1β↓, IL2↓, IL8↓, TNF-α↓,
Showing Research Papers: 1 to 6 of 6
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
Fenton↑, 1, H2O2↑, 1, ROS↓, 1, ROS↑, 1,
Mitochondria & Bioenergetics ⓘ
ATP↓, 1, MMP↓, 1,
Core Metabolism/Glycolysis ⓘ
GlutMet↓, 1, SIRT1↓, 1, SREBP1↓, 1,
Cell Death ⓘ
p‑Akt↓, 1, Apoptosis↑, 1, Bak↑, 1, BAX↑, 1, Bcl-2↓, 1, Bcl-xL↓, 1, Casp↑, 1, Casp3↑, 1, Cyt‑c↑, 2, HGF/c-Met↓, 1, MAPK↓, 1, p27↑, 1, Telomerase↓, 2,
Kinase & Signal Transduction ⓘ
p‑p70S6↓, 1,
Transcription & Epigenetics ⓘ
HATs↑, 1,
DNA Damage & Repair ⓘ
DNMTs↓, 1, P53↑, 1, PARP↑, 1,
Cell Cycle & Senescence ⓘ
CDK4↓, 1, P21↑, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
CD44↓, 1, EMT↓, 1, ERK↓, 1, HDAC↓, 2, IGF-1↓, 1, IGFBP3↑, 1, mTOR↓, 1, NOTCH↓, 1, PI3K↓, 1, PTEN↑, 1, STAT3↓, 1, TumCG↓, 2, Wnt↓, 2,
Migration ⓘ
CA↓, 1, Ca+2↑, 1, E-cadherin↑, 1, FAK↓, 1, miR-203↑, 1, MMP2↓, 1, MMP9↓, 2, MMPs↓, 1, PDGF↓, 1, TGF-β↓, 1, TIMP1↑, 1, Treg lymp↓, 1, TumCMig↓, 2, TumCP↓, 2, uPA↓, 2, Vim↓, 1, Zeb1↓, 1,
Angiogenesis & Vasculature ⓘ
angioG↓, 1, EGFR↓, 1, Hif1a↓, 2, Hif1a↝, 1, TAMS↓, 1, VEGF↓, 2,
Barriers & Transport ⓘ
NHE1↓, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, IL1↓, 1, IL1β↓, 1, IL2↓, 1, IL8↓, 1, NF-kB↓, 1, PD-L1↓, 1, PGE2↓, 1, PSA↓, 1, TNF-α↓, 1,
Hormonal & Nuclear Receptors ⓘ
AR↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 6, ChemoSen↑, 1, Dose↑, 1, Dose↝, 4, eff↝, 1, Half-Life↓, 1, Half-Life↝, 6, selectivity↑, 1,
Clinical Biomarkers ⓘ
AR↓, 1, EGFR↓, 1, PD-L1↓, 1, PSA↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, cardioP↑, 1, chemoP↑, 2, ChemoSideEff↓, 1, hepatoP↑, 1, OS↑, 1, toxicity↝, 1, toxicity∅, 1,
Total Targets: 98
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
antiOx↑, 1, NRF2↑, 1, RNS↓, 1, ROS↓, 1, SOD1↑, 1, SOD2↑, 1,
Core Metabolism/Glycolysis ⓘ
SIRT1↑, 1,
Cell Death ⓘ
iNOS↓, 1,
Transcription & Epigenetics ⓘ
other↓, 1,
DNA Damage & Repair ⓘ
P53↓, 1,
Cell Cycle & Senescence ⓘ
E2Fs↑, 1,
Proliferation, Differentiation & Cell State ⓘ
IGF-1R↓, 1,
Migration ⓘ
AP-1↓, 1, MMP2↓, 1, TIMP1↓, 1,
Angiogenesis & Vasculature ⓘ
PDGFR-BB↓, 1,
Barriers & Transport ⓘ
BBB↑, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, IL6↓, 1, IL8↓, 2, Inflam↓, 2, JAK↓, 1, NF-kB↓, 1, TNF-α↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 2, BioAv↑, 2, BioAv↝, 1, Dose↝, 1, Half-Life↝, 1,
Clinical Biomarkers ⓘ
IL6↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, cardioP↑, 1, hepatoP↓, 1, neuroP↑, 1, toxicity↓, 1,
Total Targets: 35
Scientific Paper Hit Count for: Half-Life, Half-Life
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:0 Cells:% prod#:% Target#:1109 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid
Home Page